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Abstract X-inactivation, the molecular mechanism
enabling dosage compensation in mammals, is tightly
controlled during mouse early embryogenesis. In the
morula, X-inactivation is imprinted with exclusive silenc-
ing of the paternally inherited X-chromosome. In contrast,
in the post-implantation epiblast, X-inactivation affects
randomly either the paternal or the maternal X-chromo-
some. The transition from imprinted to random X-inacti-
vation takes place in the inner cell mass (ICM) of the
blastocyst from which embryonic stem (ES) cells are
derived. The trigger of X-inactivation, Xist, is speciﬁcally
downregulated in the pluripotent cells of the ICM, thereby
ensuring the reactivation of the inactive paternal X-chro-
mosome and the transient presence of two active X-chro-
mosomes. Moreover, Tsix, a critical cis-repressor of Xist,i s
upregulated in the ICM and in ES cells where it imposes a
particular chromatin state at the Xist promoter that ensures
the establishment of random X-inactivation upon differ-
entiation. Recently, we have shown that key transcription
factors supporting pluripotency directly repress Xist and
activate Tsix and thus couple Xist/Tsix control to pluripo-
tency. In this manuscript, we report that Rnf12, a third
X-linked gene critical for the regulation of X-inactivation,
is under the control of Nanog, Oct4 and Sox2, the three
factors lying at the heart of the pluripotency network. We
conclude that in mouse ES cells the pluripotency-associ-
ated machinery exerts an exhaustive control of X-inacti-
vation by taking over the regulation of all three major
regulators of X-inactivation: Xist, Tsix, and Rnf12.
Introduction
In her seminal manuscripts proposing random X-inactiva-
tion as the mechanism underlying dosage compensation in
mammals (Lyon 1961;L y o n1962), Mary Lyon suggested
this process must occur early during female embryonic
development, around the formation of the late blastocyst.
This ﬁrst approximation was conﬁrmed by means of single
cell blastocyst injections (Gardner and Lyon 1971), cyto-
genetical observation of the heterochromatic X-chromo-
some (Plotnick et al. 1971; Takagi and Sasaki 1975), and
biochemical analysis of X-linked genes encoding meta-
bolic enzymes at different developmental stages (Monk
and Kathuria 1977): these studies established that cells of
the inner cell mass (ICM) of the blastocyst carry two active
X-chromosomes, whilst in the trophectoderm the paternally
inherited X-chromosome is inactivated. The idea that
emerged from this was that X-inactivation is initially
established upon differentiation, either imprinted in extra-
embryonic tissues or randomly in the embryo proper. This
enduring concept was well supported by analysis of
embryonic stem (ES) cells: random X-inactivation is only
established upon differentiation (Rastan and Robertson
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X-inactivation process, and their study in the pre-implan-
tation embryo challenged this initial dogma (reviewed in
Navarro and Avner 2009). In particular, the discovery of
the X-linked non-coding Xist gene (Brown et al. 1991;
Borsani et al. 1991; Brockdorff et al. 1991) and of the
mechanisms by which it triggers X-inactivation in cis, were
critical milestones.
Xist produces a 17 kb-long non-coding RNA exclusively
expressed from the inactive X-chromosome (Xi) of female
cells that mediates X-wide silencing. Xist RNA structures a
nuclear compartment from which the transcriptional
machinery is excluded and members of the Polycomb
group recruited, leading to the silencing of X-linked genes
and the initiation of a cascade of chromatin events that end
up with the heterochromatinisation of the X-chromosome
(reviewed in Ng et al. 2007). In both male and female ES
cells, Xist is consistently repressed and this might be suf-
ﬁcient to keep all X-chromosomes active (Xa) (reviewed in
Navarro and Avner 2009). Indeed, forced expression of
Xist in ES cells leads to X-inactivation even before dif-
ferentiation (Wutz and Jaenisch 2000), indicating that Xist
repression is the most critical event required to abolish
X-inactivation in undifferentiated cells. Notably, upon
differentiation, Xist is monoallelically upregulated exclu-
sively in female cells, thereby triggering random X-inac-
tivation (reviewed in Navarro and Avner 2009). The
analysis of Xist RNA and associated heterochromatin
marks in early mouse embryos radically changed our
conception of the developmental dynamics of X-inactiva-
tion (Mak et al. 2004; Okamoto et al. 2004). Although all
cells of the ICM appeared to lack an Xi, the cells of the
cleavage-stage morula were found to carry an Xi. Further,
it was shown that in the morula, the Xi is always the
paternal X-chromosome. Therefore, X-inactivation is
established much earlier than previously thought, at the two
to four cells transition, under the form of imprinted
X-inactivation. The acquisition of pluripotency, a charac-
teristic restricted to the cells of the ICM, and more par-
ticularly the expression of Nanog (Chambers et al. 2003), a
critical transcription factor specifying pluripotency, leads
to the reactivation of the paternal Xi exclusively in the
ICM (Silva et al. 2009). Strikingly, Xist silencing and Xi
reactivation also accompany the acquisition of pluripo-
tency in vitro, either after somatic-ES cells fusions (Tada
et al. 2001), nuclear cloning (Eggan et al. 2000), or the
generation of induced pluripotent stem cells (Stadtfeld
et al. 2008). Understanding how X-inactivation is abolished
in pluripotent cells is, therefore, important not only for
X-inactivation, but also to the wider ﬁeld of epigenetics
and cellular reprogramming.
Previously, we have shown that Nanog, Oct4 and
Sox2, the three main transcription factors supporting
pluripotency (reviewed in Chambers and Tomlinson
2009), bind within Xist intron 1 in ES cells and maintain
Xist repression until differentiation (Navarro et al. 2008).
This provided a simple scenario accounting for the sys-
tematic coupling of Xi reactivation with the acquisition of
pluripotency. In contrast to our expectations, however, the
deletion of Xist intron 1 is not accompanied by increased
levels of Xist expression in undifferentiated female ES
cells (Barakat et al. 2011). This indicates that Nanog,
Oct4 and Sox2 action at Xist is not sufﬁcient by itself to
keep Xist in check in undifferentiated ES cells. Hence,
additional ES-speciﬁc repressive mechanisms of Xist must
exist. In this scenario, the strong ES-speciﬁc activity of
Tsix, a non-coding antisense chromatin repressor of Xist
(Navarro et al. 2005, 2006; Sado et al. 2005; Sun et al.
2006, Ohhata et al. 2008, Navarro et al. 2009), and the
fact that other pluripotency-associated factors, namely
Klf4, c-Myc and Rex1, couple Tsix activity to pluripo-
tency (Navarro et al. 2010), is compelling. However,
neither Xist intron 1 deletion (Barakat et al. 2011) nor
Tsix deletion (Lee and Lu 1999) can individually trigger
the level of Xist upregulation that is compatible with the
initiation of X-inactivation in undifferentiated ES cells. It
remains possible that abrogating simultaneously both
pluripotency-coupled repressive arms might be sufﬁcient
to do so. An alternative, not mutually exclusive, hypoth-
esis involves a third gene recently incorporated to the
short list of X-linked regulators of X-inactivation: Rnf12,
a gene encoding an E3 ubiquitin ligase.
Rnf12, located several hundred kilobases upstream of
Xist/Tsix, was initially identiﬁed as an inducer of Xist
upregulation during random X-inactivation (Jonkers et al.
2009). Subsequently, the involvement of Rnf12 during
imprinted X-inactivation was demonstrated (Shin et al.
2010). Transgenic male ES cells overexpressing Rnf12
induce ectopic inactivation of the single X-chromosome
upon differentiation, and in female lines a large fraction of
the cells inactivates both X-chromosomes (Jonkers et al.
2009). Thus, it appears that Xist upregulation is triggered in
differentiating female cells by virtue of the two copies of
Rnf12 that they carry, as opposed to the single copy present
in male cells (Jonkers et al. 2009). In agreement, Rnf12 has
been shown to act in trans on the minimal Xist promoter
region without interfering with Nanog, Oct4, Sox2, and
Tsix activity (Barakat et al. 2011). Importantly, in female
ES cells overexpressing Rnf12, a signiﬁcant proportion of
cells already displays Xist RNA accumulation before dif-
ferentiation (Jonkers et al. 2009). This signiﬁes that, to
ensure Xi reactivation in pluripotent cells, Rnf12 expres-
sion must be downregulated. In this manuscript, we dem-
onstrate the control mediated by pluripotency-factors on
X-inactivation includes the downregulation of Rnf12 by
Nanog, Oct4 and Sox2.
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Cell lines
All lines used in this study have been previously described.
The inducible deletion of Nanog was performed by treating
RCNbH cells with tamoxifen. These cells carry: (1) an
homozygous deletion of Nanog endogenous alleles, (2) a
Cre:ERT2 expressing transgene at the Rosa26 locus, and
(3) a loxP-ﬂanked Nanog expressing transgene randomly
integrated (Chambers et al. 2007). These cells were pre-
viously used to generate Nanog-null cells by plating
tamoxifen treated cells at clonal density and expanding
Nanog-null clones (RCNbH(t)) (Chambers et al. 2007). To
restore Nanog expression in RCNbH(t) cells, a Nanog
expression vector carrying a puromycin resistance gene
was electroporated and cells selected for 6 days in the
presence of 1 lg/ml of puromycin.
Nanog-overexpressing cells (EF4) were generated by
random integration of CAG-driven Nanog cDNA in wild-
type E14Tg2a ES cells (Chambers et al. 2003).
Oct4 inducible knock-out cells have been previously
described (Niwa et al. 2000). Brieﬂy, these cells carry two
Oct4-null alleles and Oct4 expression is sustained by a
doxycycline suppressible transgene. Treatment of these
cells with 1 lg/ml of doxycycline triggers rapid and efﬁ-
cient silencing of the Oct4 expressing transgene.
Chromatin immunoprecipitation
Twenty million cells were resuspended in 3 ml of pre-
warmed DMEM-FCS 10% and crosslinked with 1%
formaldehyde (Sigma) for 10 min at room temperature.
The reaction was quenched with 0.125 mM glycine for
5 min at room temperature. Cells were spun down for
3 min at 1,300 rpm at 4C, and washed twice with cold
PBS-1X (Invitrogen). Cell pellets were then vigorously
resuspended in 300 ll of swelling buffer (5 mM Pipes pH
8, 85 mM KCl) freshly supplemented with 1X protease
inhibitor cocktail (Roche) and 0.5% NP-40. The suspension
was incubated for 20 min on ice with occasional shaking.
Nuclei were spun down in 15 ml conical tubes for 10 min
at 1,500 rpm at 4C and resuspended in 1.5 ml of TSE150
(0.1% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris–HCl
pH 8, 150 mM NaCl) buffer, freshly supplemented with 1X
protease inhibitor cocktail. Samples were sonicated at 4C
in 15 ml conical tubes using a Bioruptor (Diagenode) for 5
cycles of 10 min divided into 30 s ON-30 s OFF subcycles
at maximum power. Chromatin was then transferred into
1.5 ml tubes and centrifuged for 30 min at 14,000 rpm at
4C. Soluble chromatin was aliquoted and stored at -80C
until use. Twenty microlitres were used for quantity and
quality controls of the DNA.
For each experiment, the required amount of chromatin
was defrosted and pre-cleared for 1h30 with rotation at
4C in 1 ml of TSE150 with 50 ll of pA/pG Sepharose
beads (Sigma) 50% slurry, previously blocked with
500 lg/ml of molecular grade BSA (Roche) and 1 lg/ml
of yeast tRNA (Invitrogen). Pre-cleared chromatin was
transferred into fresh tubes after 1 min centrifugation at
3,000 rpm and aliquoted accordingly (20 lg of DNA per
ChIP). Twenty micrograms of diluted chromatin were
aliquoted for input DNA extraction and precipitation.
Immunoprecipitation with speciﬁc antibodies [1 lg home-
made rabbit anti-Nanog (Mullin et al. 2008), 1 lg goat
anti-Oct4 (Santa Cruz, sc-8628), 1 lg goat anti-Sox2
(Santa Cruz, sc-17320)] was performed overnight with
rotation at 4C, in a ﬁnal volume of 500 ll. Immuno-
complexes were recovered with 50 ll of blocked pA/pG
Sepharose beads 50% slurry for 1h30 with rotation at
4C. Beads were recovered by 1 min centrifugation at
3,000 rpm and washed at room temperature in 1 ml of
TSE150, TSE500 (0.1% SDS, 1% Triton, 2 mM EDTA,
20 mM Tris–HCl pH8, 500 mM NaCl), washing buffer
(10 mM Tris–HCl pH8, 0.25 M LiCl, 0.5% NP40, 0.5%
Na-Deoxycholate, 1 mM EDTA), and twice in TE
(10 mM Tris–HCl pH8, 1 mM EDTA). Each wash was
performed for 5 min with rotation at room temperature.
After the last wash, elution was performed in 100 llo f
elution buffer (1% SDS, 10 mM EDTA, 50 mM Tris–HCl
pH8) for 15 min at 65C after vigorous vortexing. Eluates
were collected after 1 min centrifugation at 14,000 rpm,
and the beads rinsed in 150 ll of TE-SDS 1%. After
1 min centrifugation at 14,000 rpm, the supernatant was
pooled with the corresponding ﬁrst eluate. Crosslinking of
ChIP and input fractions was reversed overnight at 65C,
followed by proteinase K treatment (invitrogen), phenol/
chloroform extraction and ethanol precipitation. DNA
pellets corresponding to the input fractions were resus-
pended in 300 ll of water, whilst those corresponding to
the ChIP fraction were resuspended in 150 ll.
RNA extraction and reverse transcription
One to ﬁve million cells were lysed in TRIZOL (Invitro-
gen) and RNA was then chloroform extracted and isopro-
panol precipitated. After DNase treatment (Quiagen), RNA
was phenol/chloroform re-extracted, ethanol precipitated,
resuspended in water and quantiﬁed.
One to 4 lg of RNA were used per RT reaction. RNA
was denatured in the presence of 1 lg of random hexamers
(Roche) for 5 min at 90C, and reverse transcribed in a
ﬁnal volume of 20 ll with 100 U of SuperScriptII (Invit-
rogen) at 42C for 60 min followed by heat inactivation at
70C for 15 min. Synthesised cDNAs were diluted in
280 ll of water and stored at -20C until used.
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Q-PCR was performed in 384-well plates with a 480
LightCycler (Roche) using LightCycler 480 SYBR Green I
Master (Roche). All reactions were performed in duplicate.
Five microliters of DNA were used per reaction.
Standard curves of all primers were performed to check
for efﬁcient ampliﬁcation (above 90%). Melting curves
were also generated to verify production of single DNA
species with each primer pair. All primer sequences are
available upon request.
Relative levels of expression in each RT-(Q)PCR assay
were obtained through the DDCt method, using Tbp mRNA
levels as a reporter in all experiments.
Enrichment levels in ChIP assays are expressed as
enrichment levels as compared to the Actin promoter.
Essentially, for each analysed position, the DCt method
was used to calculate a ChIP over input ratio that was
corrected by the appropriate dilution factor of each ana-
lysed fraction. To calculate enrichment levels, values
obtained for the Rnf12 upstream region were divided by
those obtained for the Actin promoter.
Primer pairs to detect binding of Nanog, Oct4 and Sox2
upstream of Rnf12 were designed across positive ChIP-Seq
hits publicly available (Chen et al. 2008). The Actin pro-
moter was chosen as a negative control on the basis of the
absence of binding observed in the same data set. The
sequences are: Rnf12-4 kb F: CAGCCTCTGGCTCTACC
AGTandR:GTGACCTGCTGGGGAGAATA;Rnf12-5 kb
F: GCCTGTCAAACGTCCTGTTTA and R: GGAGGTTG
TGGGAGAAACAA; Actin F: CCGTTCCGAAAGTTG
CCTT and R: CGCCGCCGGGTTTTATA.
Results
Rnf12 is a target of Nanog in undifferentiated mouse ES
cells
Rnf12 protein levels have been shown to increase moder-
ately during ES cells differentiation (Barakat et al. 2011).
To assess whether this increase is mediated by an increase
of mRNA levels, we ﬁrst conducted RT-(Q)PCR in
undifferentiated and differentiating ES cells. Efﬁcient dif-
ferentiation was evaluated by measuring Nanog mRNA
levels, and as expected we found consistent downregula-
tion of Nanog after 3 days of RA-mediated differentiation
(Fig. 1a). Under these conditions, we found a two to
threefold increase of Rnf12 expression in RA-differentiated
cells, in both males (E14Tg2a) and females (LF2) though
the absolute levels of Rnf12 mRNA showed the expected 2
to 1 ratio between XX and XY cells (Fig. 1b). This sug-
gests that similar principles of regulation of Rnf12 apply
during male and female differentiation and that the sole
presence of two alleles in females underlies the female-
speciﬁc action of Rnf12.
The correlation between Nanog downregulation and
Rnf12 upregulation during ES cells differentiation, and the
fact that in the embryo the reactivation of the Xi closely
follows Nanog protein expression in the ICM (Silva et al.
2009), suggests that Nanog might be important for Rnf12
regulation. Interestingly, genome-wide analysis suggests
Rnf12 might be a direct target of Nanog (Chen et al. 2008).
To conﬁrm this, we determined whether two regions
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Nanog  mRNA
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b
Rnf12  mRNA
30
45
0
LF2 LF2 RA E14Tg2a E14Tg2a RA
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15
LF2 LF2 RA E14Tg2a E14Tg2a RA
Nanog
6
Actin
Rnf12 (-4kb)
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3
E14Tg2a E14Tg2a RA
Rnf12 (-5kb)
Fig. 1 Rnf12 is a direct target of Nanog in ES cells. Male (E14Tg2a)
and female (LF2) ES cells were differentiated with retinoic acid for
3 days, and Nanog (a) and Rnf12 (b) mRNA levels measured by RT-
(Q)PCR before and after treatment. Statistical signiﬁcance of Rnf12
expression differences was assessed with a paired t test [p value of
LF2-d3/d0 \0.03 (n = 3) and of E14Tg2a-d3/d0 \0.01 (n = 3)].
c ChIP analysis of Nanog binding at two regions located 4 and 5 kb
upstream of the transcription start site in undifferentiated and RA-
differentiated male ES cells. All values represent averages of
independent cell cultures ± SEM
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123located 4 and 5 kb upstream of Rnf12 and identiﬁed by
ChIP-Seq as positive Nanog hits (Chen et al. 2008) show
enrichment for Nanog in ChIP-(Q)PCR assays. A ﬁve to
sixfold enrichment was measured at these two regions in
undifferentiated ES cells but not in RA-differentiating
negative controls (Fig. 1c). These results, therefore, sug-
gest that Nanog is a direct regulator of Rnf12 in undiffer-
entiated ES cells.
Nanog acts as a repressor of Rnf12 expression
in undifferentiated ES cells
The negative correlation existing between Nanog binding
and Rnf12 expression during ES cells differentiation
(Fig. 1) suggests that Nanog may act as a negative regu-
lator of Rnf12. To assess the modality of Nanog action at
Rnf12, we ﬁrst analysed the consequences of over-
expressing Nanog. To do this, we used a cell line (EF4)
carrying a randomly integrated Nanog-expressing trans-
gene (Chambers et al. 2003) that confers high levels of
Nanog mRNA expression (Fig. 2a). In EF4, binding of
Nanog at both the -4 and -5 kb regions of the Rnf12 locus
is greatly increased, with enrichment levels being around
two to threefold higher than in control E14Tg2a ES cells
(Fig. 2b). Given the fact that in EF4 cells Nanog protein is
elevated approximately ﬁvefold relative to wild-type cells
(Yates and Chambers 2005), this implies that Nanog
binding at Rnf12 in wild-type cells is not saturated, at least
at the population level, though it may be saturated in EF4
cells. Since in wild-type cells Nanog is heterogeneously
expressed (Chambers et al. 2007), with a signiﬁcant frac-
tion expressing low or undetectable Nanog protein, the
increase of binding in EF4 likely reﬂects the homogeneity
of Nanog expression and binding achieved by means of
transgenic Nanog expression. Importantly, in EF4 ES cells,
the expression of Rnf12 is reduced by about 50% (Fig. 2c).
To consolidate this observation, we took advantage of
Nanog-null ES cells (RCNbH(t), Chambers et al. 2007)i n
which neither Nanog expression (Fig. 2a) nor binding at
Rnf12 are detected (Fig. 2b). In these cells, Rnf12 tran-
scripts were found upregulated by around twofold, as
expected for Nanog acting as a repressor (Fig. 2c). Next,
we investigated whether Rnf12 upregulation is a primary,
early consequence of Nanog depletion. To do this, we used
RCNbH cells, the parental line of RCNbH(t). In RCNbH
ES cells, both Nanog alleles have been deleted and Nanog
expression is supported by a randomly integrated transgene
in which the Nanog open reading frame is ﬂanked by loxP
sites. Moreover, RCNbH express a Cre:ERT2 fusion pro-
tein from the constitutive Rosa26 locus. Upon treatment of
these cells with tamoxifen, the Cre:ERT2 fusion protein
translocates into the nucleus and mediates the deletion of
the Nanog-expressing transgene (Chambers et al. 2007).
RCNbH cells were treated with tamoxifen for 3 days and
RNAs collected daily. Nanog mRNA levels decrease
strongly within the ﬁrst 24 h of treatment, and reach
background levels after 48 h (Fig. 3a). Within the ﬁrst 24 h
of tamoxifen treatment, Rnf12 mRNA increases to levels
similar to that detected in established Nanog-null cells
(Fig. 3b). Together with our ChIP analysis, this result
suggests that the alteration of Rnf12 expression observed in
established Nanog-null or overexpressing lines is due to a
direct action of Nanog on Rnf12.
Next, we tested the reversibility of Rnf12 upregulation
observedinNanog-nullcells.Todothis,aNanog-expression
vector was stably integrated inRCNbH(t)EScells and RNA
a
Nanog  mRNA
100
200
b
0
E14Tg2a EF4 RCNβH(t)
Nanog
10
20
Actin
Rnf12 (-4kb)
Rnf12 (-5kb)
c
Rnf12  mRNA
10
15
0
E14Tg2a EF4 RCNβH(t)
0
5
E14Tg2a EF4 RCNβH(t)
Fig. 2 Rnf12 is downregulated by Nanog in ES cells. Analysis of
Nanog mRNA levels (a) binding at the Rnf12 locus (b) and Rnf12
mRNA levels (c) in wild-type E14Tg2a ES cells, Nanog-overexpress-
ing ES cells (EF4), and Nanog-null ES cells (RCNbH(t)). All values
represent averages of independent cell cultures ± SEM. Statistical
signiﬁcance of Rnf12 expression differences was assessed with an
unpaired t test [p value of EF4/wt\0.03 (n = 3) and of RCNbH(t)/wt
\0.03 (n = 3)]
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123and chromatin prepared. Evaluation of Nanog mRNA levels
(Fig. 4a) indicates restoration of Nanog expression to levels
similar to thatof wild-typeEScells(Fig. 1a),indicating that
the analysis is performed in physiological conditions
regardingthelevelofNanogexpression.Comparedtoempty
vector transfectants, the re-expression of Nanog in Nanog-
null cells leads to efﬁcient binding of Nanog at the -4 and
-5 kb sites of the Rnf12 upstream region (Fig. 4b), with
identical levels ofenrichment tothoseobserved inwild-type
cells (Fig. 1c). Under these conditions, Rnf12 mRNA levels
(Fig. 4c) decline back to wild-type levels (Fig. 1b), whilst
the cells transfected with the empty vector express similar
levels of Rnf12 than untransfected RCNbH(t) ES cells
(Fig. 2c). Taking all our observations together, we conclude
thatNanogactsasareversiblerepressorofRnf12expression
in ES cells.
Nanog-independent binding of Oct4 and Sox2
at the Rnf12 upstream region
In the absence of Nanog binding to the Rnf12 upstream
region, Rnf12 is twofold upregulated in male ES cells.
However, the level reached in differentiating male ES cells
is about threefold as compared to that observed in wild-
type undifferentiated cells. This indicates that Nanog
depletion in ES cells does not recapitulate entirely the
mechanisms leading to Rnf12 upregulation during differ-
entiation. Additional repressors of Rnf12 might exist in ES
cells.
Genome-wide localisation studies of transcription factor
binding in ES cells have shown that Nanog tends to bind at
chromatin sites overlapping or just adjacent to those bound
by Oct4 and Sox2 (Chen et al. 2008). More importantly, at
Xist intron 1 Nanog binds with Oct4 and Sox2 to repress
Xist transcription (Navarro et al. 2008). Therefore, we
a
Nanog mRNA
60
0
30
RCNβH d0 RCNβH d1 RCNβH d2 RCNβH d3
b
Rnf12 mRNA
5
10
15
0
RCNβH d0 RCNβH d1 RCNβH d2 RCNβH d3
Fig. 3 Rnf12 upregulation arises rapidly following Nanog depletion.
Analysis of Nanog (a) and Rnf12 (b) mRNA levels in inducible
Nanog-null RCNbH cells treated with tamoxifen for the indicated
number of days. All values represent averages of independent cell
cultures ± SEM. Statistical signiﬁcance of Rnf12 expression differ-
ences was assessed with a paired t-test. Although there is a clear trend
from day 1 onwards, clear statistical signiﬁcance is only reached after
3 days of treatment [p value of d3/d0\0.03 (n = 10)], when Nanog
expression is reduced to about 0.1% of untreated cells
a
Nanog mRNA
20
40
b
Nanog
3
6
Actin
Rnf12 (-4kb)
Rnf12 (-5kb)
0
RCNβH(t) + Nanog RCNβH(t) + EmptyVector
c
0
RCNβH(t) + Nanog RCNβH(t) + EmptyVector
Rnf12 mRNA
10
15
0
5
RCNβH(t) + Nanog RCNβH(t) + EmptyVector
Fig. 4 Rnf12 upregulation in Nanog-null ES cells is reversible.
Analysis of Nanog mRNA levels (a) binding at the Rnf12 locus
(b) and Rnf12 mRNA levels (c) in RCNbH(t) Nanog-null cells
transfected with either a Nanog-expression vector or an empty vector.
All values represent averages of independent cell cultures ± SEM.
Statistical signiﬁcance of Rnf12 expression differences was assessed
with a paired t test (p value of Nanog/empty\0.03 (n = 3)]
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123hypothesised that Oct4 and Sox2 bind with Nanog at the
Rnf12 upstream region. We performed ChIP assays with
Oct4 (Fig. 5a) and Sox2 (Fig. 5b) antibodies in ES cells.
Both factors were found to bind at the -4 and -5 kb sites
of the Rnf12 upstream region, with levels of enrichment
about four to ﬁvefold higher than those measured at the
beta-actin negative control. Importantly, in RA-treated
differentiating ES cells, binding of both Oct4 and Sox2 is
totally abolished. This result suggests that Oct4 and Sox2
cooperate with Nanog to bring about efﬁcient downregu-
lation of Rnf12.
To determine if Nanog is required or at least inﬂuences
the binding of Oct4 and Sox2 at the Rnf12 locus, we ﬁrst
analysed Oct4 and Sox2 binding at the -4 and -5k b
regions in cells displaying increased binding of Nanog and
found that neither Oct4 nor Sox2 exhibit increased binding
at Rnf12 (EF4, Fig. 5a, b). Moreover, in Nanog-null ES
cells both Oct4 and Sox2 remain associated to the Rnf12
upstream region at levels of enrichment indistinguishable
from those observed in wild-type E14Tg2a ES cells
(RCNbH(t), Fig. 5a, b). We conclude that Oct4 and Sox2
bind at the Rnf12 locus in a Nanog-independent fashion.
Inappropriate high levels of Rnf12 expression
in inducible Oct4-null male ES cells
Should Oct4 and Sox2 act as repressors of Rnf12, then their
permanent binding in the absence of Nanog might explain
the mild upregulation of Rnf12 observed in Nanog-null ES
cells. This situation would be strikingly similar to that
previously observed for Xist. In the absence of Nanog, Xist
is moderately upregulated in undifferentiated male ES
cells. However, the acute silencing of Oct4 experimentally
triggered in inducible Oct4-null male ES cells leads to
differentiation and ectopic accumulation of Xist RNA at
levels compatible with X-inactivation (Navarro et al.
2008). We sought to test whether in these particular con-
ditions Rnf12 is expressed at female-like mRNA levels. To
do this, we used ZHBTc4 male ES cells (Niwa et al. 2000).
In these cells, both Oct4 alleles are deleted and a doxy-
cycline-repressible Oct4 transgene supports Oct4 expres-
sion. Twenty-four hours after addition of doxycycline,
Oct4 mRNA levels are completely abolished, whilst Nanog
and Sox2 remain expressed (Online Resource 1). This is
associated with a 2 to threefold increase of Rnf12 expres-
sion (Fig. 5c), indicating that Oct4 acts as a repressor of
Rnf12. Strikingly, after 4 days of treatment, when Nanog
and Sox2 are silenced (Online Resource) and Xist RNA
levels were previously shown to be similar to those mea-
sured in differentiating female ES cells, Rnf12 expression
further increases to levels compatible with X-inactivation
as evaluated in differentiating female ES cells (Fig. 5c).
Therefore, we conclude that Rnf12 regulation by Nanog,
Oct4 and Sox2 follows virtually identical principles than
Xist regulation: Nanog, Oct4 and Sox2 synergistically
downregulate Rnf12 in undifferentiated ES cells.
Discussion
Previously, we and others have shown that in undifferen-
tiated ES cells Xist is silenced by two independent
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Fig. 5 Oct4 and Sox2 also act as Rnf12 repressors in ES cells.
Analysis of Oct4 (a) and Sox2 (b) binding at the Rnf12 upstream
region in the indicated cell lines. (c) Comparison of Rnf12 expression
in different cell lines and conditions. ZHBTc4 ES cells are
doxycycline inducible Oct4-null ES cells. All values represent
averages of independent cell cultures ± SEM. Statistical signiﬁcance
of Rnf12 expression differences in doxycycline-treated ZHBTc4 cells
was assessed with a paired t test [p value of d1/d0 and d4/d0\0.01
(n = 6 and 4, respectively)]. An unpaired t test further conﬁrmed that
the level of Rnf12 mRNA reached in doxycycline-treated ZHBTc4 is
signiﬁcantly higher than that measured in RA-treated E14Tg2a cells
(p value\0.01)
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123mechanisms: (1) a direct transcriptional repression medi-
ated by Nanog, Oct4 and Sox2 binding at Xist intron 1
(Navarro et al. 2008), and (2) a chromatin repression
mediated by Tsix (reviewed in Navarro and Avner 2010),
which is upregulated by the direct action of c-Myc, Klf4
and Rex1 binding at the primary Tsix enhancer DXPas34
(Navarro et al. 2010) and by Oct4, Sox2 and Klf4 binding
at the secondary Tsix enhancer Xite (Donohoe et al. 2009;
Navarro et al. 2010). Neither Xist intron 1 deletion (Barakat
et al. 2011), nor Tsix mutation (Lee and Lu 1999) is indi-
vidually able to trigger X-inactivation in undifferentiated
ES cells, suggesting that either both systems cooperate to
silence Xist, and/or that other systems of repression act in
ES cells. It must be mentioned, however, that further
analyses of the effects of Xist intron 1 deletion are required
before rigorously concluding that it does not strongly affect
Xist regulation. In undifferentiated ES cells, the Xist pro-
moter is unable to efﬁciently recruit the transcriptional
machinery, regardless of Tsix activity (Navarro et al. 2005).
However, in the absence of Tsix, Xist RNA levels increase
considerably in undifferentiated ES cells (Morey et al.
2001; Vigneau et al. 2006), suggesting Tsix might have
post-transcriptional effects on Xist expression. Therefore, it
is possible that in the absence of Xist intron 1, the tran-
scriptional machinery is indeed efﬁciently recruited at the
Xist promoter, Xist transcription readily enhanced, but Xist
RNA post-transcriptionally repressed by Tsix RNA. Thus, a
ChIP analysis of Xist promoter state in Xist intron 1-deleted
ES cells is absolutely required. Also, the analysis of double
Xist intron 1/Tsix-mutants is required, and future work
should speciﬁcally address this critical point.
Despite these considerations, additional mechanisms
coupled to pluripotency might be involved in Xist suppres-
sion in ES cells. In this context, the results we report here
expand our previous work on the coupling between
X-inactivation and pluripotency regulators. Indeed, we
demonstrate Rnf12 is downregulated by Nanog, Oct4 and
Sox2,thethreemainactorsofpluripotency.Interestingly,the
sole overexpression of Rnf12 in female ES cells leads to
X-inactivation in the undifferentiated state (Barakat et al.
2011). Although the mechanisms of Rnf12 action at Xist are
unknown, good evidence suggests it may activate the Xist
promoter(Barakatetal.2011).Therefore,thefactthatRnf12
is downregulated by Nanog, Oct4 and Sox2 appears to be of
critical importance in maintaining Xist silencing in undif-
ferentiated ES cells. It is noteworthy that in all Nanog- and
Oct4-null experimental conditions in which we previously
reported ectopic Xist upregulation in male cells (Navarro
et al. 2008), Rnf12 is also upregulated. Given the positive
action exerted by Rnf12 on Xist, this suggests that all our
previous observations on Xist might at least in part be due to
Rnf12 upregulation rather than to a direct action of Nanog,
Oct4andSox2throughXistintron1binding.Ifthiswastobe
true, the binding of these factors to Xist intron 1 would be
extremely mysterious and perhaps functionally linked to the
choice of the X-chromosome to be inactivated, as recently
suggested (Barakat et al. 2011). We reiterate, however, that
further work on the effects of Xist intron 1 deletion in
undifferentiated ES cells is necessary before reaching these
conclusions. Similarly, unequivocal proof that the binding
events we have identiﬁed here directly inhibit Rnf12 tran-
scription should be provided in the future by targeting spe-
ciﬁc mutations that abrogate the binding.
Immuno-ﬂuorescence analysis of Nanog and Rnf12 in
ES cells has previously shown that Rnf12 is only consis-
tently detected in Nanog-negative ES cells (Barakat et al.
2011). Nanog-negative and -positive cells have been shown
to interconvert (Chambers et al. 2007), implying that
Rnf12-negative and -positive cells may interconvert as
well. This suggests that Nanog action at Rnf12 is reversible
and strictly dependent on its expression, as supported by
the restoration of normal levels of Rnf12 upon re-expres-
sion of Nanog in Nanog-null ES cells. To ultimately prove
this single cell analysis, ideally by immunoﬂuorescence,
should be performed to follow the evolution of Nanog and
Rnf12 protein levels during the growth of ES clones
derived from single cells.
Initially viewed as a simple Xist-Nanog/Oct4/Sox2
connection, the system coupling X-inactivation with plu-
ripotency is rapidly expanding, ﬁrst by the inclusion of Tsix
as a direct target of Klf4, Rex1 and c-Myc, and now with
the repressive action of Nanog, Oct4 and Sox2 on Rnf12
expression (Fig. 6). Strikingly, although our study has been
restricted to Nanog, Oct4 and Sox2, additional transcrip-
tion factors such as Klf4 and Esrrb, which have important
roles in pluripotency (reviewed in Chambers and Tomlin-
son 2009), might also contribute to Rnf12 control as sug-
gested by available ChIP-Seq data sets (Online Resource
2). This leads to a remarkably complex network of func-
tional interactions between pluripotency and X-inactivation
regulators, a major emergent property of which might be
the increase of the robustness of X-inactivation inhibition
in pluripotent compartments of the early embryo such as
the ICM and the germ line. Furthermore, we believe the
number of actors and nodes of this network is likely to
grow further both by discovering other pluripotency factors
acting on Xist, Tsix and Rnf12, and by ﬁnding new
X-linked regulators of X-inactivation. For instance, two
additional X-linked non-coding genes have been recently
shown to play a role in Xist regulation in ES cells: Ftx
(Chureau et al. 2011) and Jpx (Tian et al. 2010). Both are
located between Rnf12 and Xist and have been suggested to
act as Xist activators through yet unknown mechanisms.
Although it is unknown whether Ftx and/or Jpx overex-
pression leads to X-inactivation in the undifferentiated
state, their downregulation in ES cells may be important
262 Hum Genet (2011) 130:255–264
123for keeping Xist silent before differentiation. Strikingly,
extensive binding of Nanog but not Oct4/Sox2 is observed
around Ftx in available ChIP-Seq data sets (Online
Resource 2). In contrast, Jpx does not appear in ChIP-Seq
studies as a target of Nanog or of any other pluripotency-
associated factor. Although additional work needs to be
done to elucidate whether these two non-coding genes are
also controlled by pluripotency transcription factors, it is
increasingly clear that the road to pluripotency and the path
of X-inactivation are intrinsically connected through the
direct control of many, if not all, X-inactivation regulatory
genes by the transcriptional machinery dedicated to pluri-
potency. The future establishment of the contribution of
each individual factor to the control of X-inactivation will
undoubtedly shed light on our understanding of how
genetic and epigenetic regulators functionally interact to
bring the phenotype into being.
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